A novel case of bisphosphonate-related osteonecrosis of the torus palatinus in a patient with metastatic breast cancer
A novel case of bisphosphonate-related osteonecrosis of the torus palatinus in a patient with metastatic breast cancer
复制标题
DOI：
10.1159/000106451
复制
发表时间：
2006-01-01
期刊：
影响因子：
3.5
通讯作者：
Swain, Sandra M.
中科院分区：
文献类型：
--
作者：
Goldman, Matthew L.;Denduluri, Neelima;Swain, Sandra M.
口服和静脉注射双膦酸盐可用于各种内分泌和肿瘤学适应症。长期静脉注射双膦酸类药物被证明会导致颌骨骨坏死。我们报告一个病例，一位58岁的转移性乳腺癌女性，在16个月期间接受了18剂4毫克唑来膦酸的静脉注射，并在大的小叶性腭环的后缘形成了一块骨坏死区域。腭环是上颌骨外生症的一种，在绝经后妇女中很常见，容易受到钝性创伤，容易发生骨坏死。去除死骨的死骨，4周内愈合。这一病例表明，患有腭环的患者可能有很高的骨坏死风险，并强调在接受双膦酸类药物治疗时，需要良好的口腔卫生和频繁的牙科检查。
Bisphosphonates administered orally and intravenously are used for a variety of endocrine and oncologic indications. Long- term intravenous use of bisphosphonates has been shown to cause osteonecrosis of the jaw. We report a case in which a 58- year- old woman with metastatic breast cancer received 18 doses of 4 mg intravenous zoledronic acid over a period of 16 months and developed a region of osteonecrosis on the posterior edge of a large, lobular torus palatinus. Torus palatinus, a type of maxillary exostosis, is common among postmenopausal women, and is vulnerable to blunt trauma that could predispose to osteonecrosis. Sequestrum of dead bone was removed and the site healed within 4 weeks. This case demonstrates that patients with a torus palatinus may be at high risk for osteonecrosis, and reinforces the need for good oral hygiene and frequent dental examination while receiving bisphosphonate therapy.